SVB Securities analyst Puneet Souda maintained a Buy rating on Centogene NV (CNTG – Research Report) on July 15 and set a price target of $6.00. The company’s shares closed last Tuesday at $2.13, close to its 52-week low of $1.83.
According to TipRanks.com, Souda has 0 stars on 0-5 stars ranking scale with an average return of -11.0% and a 35.2% success rate. Souda covers the Healthcare sector, focusing on stocks such as AbCellera Biologics, Castle Biosciences, and Twist Bioscience.
Currently, the analyst consensus on Centogene NV is a Moderate Buy with an average price target of $6.00.
See the top stocks recommended by analysts >>
Centogene NV’s market cap is currently $42.88M and has a P/E ratio of -0.70.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Centogene NV is a commercial-stage company. It focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. It operates through the following two segments: Pharmaceutical and Diagnostics. The Pharmaceutical segment provides services to pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery and patient monitoring. The Diagnostics segment provides targeted genetic sequencing and diagnostics services. The company was founded by Arndt Rolf and Christoph Ehlers in 2006 and is headquartered in Rostock, Denmark.
Read More on CNTG:
- Gossamer Bio (GOSS) Received its Third Buy in a Row
- Twist Bioscience (TWST) Receives a Hold from SVB Securities
- Liquidia Technologies (LQDA) Gets a Buy Rating from BTIG
- SVB Securities Maintains Their Buy Rating on Natera (NTRA)
- Analysts’ Top Industrial Goods Picks: CryoPort (CYRX), Verra Mobility (VRRM)
